Your browser doesn't support javascript.
loading
SARS-CoV-2 infection in high-risk children following tixagevimab-cilgavimab (Evusheld) pre-exposure prophylaxis: a single-center observational study.
Hijano, Diego R; Ferrolino, Jose A; Swift, Elizabeth G; Michaels, Carolyn A; Max, Anita; Hayden, Randall T; Wolf, Joshua; Dallas, Ronald H; Greene, William L; Richardson, Julie L; Hakim, Hana; Morton, Ted H; Cross, Shane J.
Afiliação
  • Hijano DR; Department of Infectious Diseases, St. Jude Children Research Hospital, Memphis, TN, United States.
  • Ferrolino JA; Department of Infectious Diseases, St. Jude Children Research Hospital, Memphis, TN, United States.
  • Swift EG; Center for Advanced Practice Providers, St. Jude Children Research Hospital, Memphis, TN, United States.
  • Michaels CA; Center for Advanced Practice Providers, St. Jude Children Research Hospital, Memphis, TN, United States.
  • Max A; Center for Advanced Practice Providers, St. Jude Children Research Hospital, Memphis, TN, United States.
  • Hayden RT; Department of Pathology, St. Jude Children Research Hospital, Memphis, TN, United States.
  • Wolf J; Department of Infectious Diseases, St. Jude Children Research Hospital, Memphis, TN, United States.
  • Dallas RH; Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, United States.
  • Greene WL; Department of Infectious Diseases, St. Jude Children Research Hospital, Memphis, TN, United States.
  • Richardson JL; Center for Advanced Practice Providers, St. Jude Children Research Hospital, Memphis, TN, United States.
  • Hakim H; Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children Research Hospital, Memphis, TN, United States.
  • Morton TH; Department of Infectious Diseases, St. Jude Children Research Hospital, Memphis, TN, United States.
  • Cross SJ; Department of Infectious Diseases, St. Jude Children Research Hospital, Memphis, TN, United States.
Front Oncol ; 13: 1229655, 2023.
Article em En | MEDLINE | ID: mdl-37601666
From 8 December 2021 to 26 January 2023, tixagevimab-cilgavimab (T-C) was authorized for pre-exposure prophylaxis of COVID-19. During this period, we used a multidisciplinary team to communicate, screen, approach, and administer T-C to eligible patients. Twenty-seven patients were eligible. Of these, 24 (88.9%) received at least one dose of T-C and three patients received two doses. Majority of patients were White, non-Hispanic, and women. Only two patients had COVID-19 prior to receiving T-C. Seventeen (70.8%) had received two or more doses of SARS-CoV-2 vaccine. No serious adverse events were noted. Seven patients developed SARS-CoV-2 infection within 180 days of receiving T-C (median 102 days; range 28-135), and only one patient developed severe COVID-19 requiring intensive mechanical ventilation in the intensive care unit.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article